As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Catalyst Pharmaceuticals agreed to settle its litigation against Lupin Pharmaceuticals over Lupin's application to market a generic version of Catalyst's Lambert-Eaton myasthenic syndrome drug.